226395-87-5

Basic information

• Product Name: N-hydroxy-4-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide hydrochloride
• Synonyms: N-hydroxy-4-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide hydrochloride
• CAS NO: 226395-87-5
• Molecular Weight: 496.892
• Mol File: 226395-87-5.mol

Chemical Properties

• CAS DataBase Reference: N-hydroxy-4-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: N-hydroxy-4-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide hydrochloride(226395-87-5)
• EPA Substance Registry System: N-hydroxy-4-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide hydrochloride(226395-87-5)

Safety Data

• Hazardous Substances Data: 226395-87-5(Hazardous Substances Data)

Upstream product

• 226401-67-8 C₂₆H₃₀F₃NO₈S 
• 828-27-3 4-Trifluoromethoxyphenol 
• 226396-63-0 1-(tert-butyl) 4-ethyl 4-[(4-fluorophenyl)sulfonyl]piperidine-1,4-dicarboxylate 
• 226400-29-9 C₂₄H₂₆F₃NO₈S 
• 226400-31-3 C₂₉H₃₅F₃N₂O₉S 

Relevant articles and documents

OPTICAL AGENTS FOR IMAGING AND VISUALIZATION OF MATRIX METALLOPROTEINASE ENZYMES

The invention relates generally to optical agents for biomedical applications including imaging, visualization, phototherapy and diagnostic monitoring of cells and tissue expressing MMPs and/or tissues associated with the expression of MMPs. In some embodiments, for example, optical agents of the present invention selectively bind to, or otherwise preferentially associate with, a target tissue expressing one or more MMPs, and function to couple electromagnetic radiation into and/or out of the target tissue, for example via optical absorption, fluorescence, scattering and/or optoacoustic processes.

Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl Sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease

α-Sulfone-α-piperidine and α-tetrahydropyranyl hydroxamates were explored that are potent inhibitors of MMPs-2,-9, and-13 that spare MMP-1, with oral efficacy in inhibiting tumor growth in mice and left-ventricular hypertrophy in rats and in the bovine cartilage degradation ex vivo explant system. α-Piperidine 19v (SC-78080/SD-2590) was selected for development toward the initial indication of cancer, while α-piperidine and α-tetrahydropyranyl hydroxamates 19w (SC-77964) and 9i (SC-77774), respectively, were identified as backup compounds.